94 filings
Page 3 of 5
8-K
tyuklye ba
6 Mar 19
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
99zy4mkty
6 Feb 19
Royalty revenue for the quarter increased to $69.9 million
4:05pm
8-K
786su76 t1mp
26 Nov 18
Royalty revenue for the quarter increased to $67.2 million
4:07pm
8-K
vi79jc2mnxrt1vur
7 Aug 18
Results of Operations and Financial Condition
12:00am
8-K
ytf3xxz dhl
8 May 18
Royalty revenue for the quarter increased to $44.0 million due to increase in AbbVie’s MAVYRET™ sales
4:05pm
8-K
b4nsz
2 Mar 18
Submission of Matters to a Vote of Security Holders
12:00am
8-K
599xno y5js6f
7 Feb 18
Total revenue for the quarter was $38.1 million
12:00am
8-K
fvxpu06otfvu p9
20 Nov 17
Total revenue for the quarter was $75.9 million
12:00am
8-K
rpb9l7x7506nc6eq
13 Sep 17
Departure of Directors or Certain Officers
12:00am
8-K
1c8 4y9h8o3p
7 Aug 17
Royalty revenue for the quarter was $7.5 million
12:00am
8-K/A
rvi1f28xcdj
9 May 17
Results of Operations and Financial Condition
12:00am
8-K
iev5htvq16s
8 May 17
R&D expense increased to $13.0 million in support of pipeline development
12:00am
8-K
rsn7qlke1qceb7 p2aa
21 Feb 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
kw71b0
8 Feb 17
Results of Operations and Financial Condition
12:00am
8-K
uau75woi o0523
6 Jan 17
Regulation FD Disclosure
12:00am
8-K
f2r77qv
22 Nov 16
Departure of Directors or Certain Officers
12:00am
8-K
ebxtnc7f6
21 Nov 16
Enanta Pharmaceuticals Reports Financial Results for its
12:00am
8-K
qethgjzgzrbb9ugtq6m
8 Aug 16
Enanta Pharmaceuticals Reports Financial Results for its
12:00am
8-K
cgkspjuw
9 May 16
Enanta Pharmaceuticals Reports Financial Results for its
12:00am
8-K
rqz bfo8gqs
16 Feb 16
Submission of Matters to a Vote of Security Holders
12:00am